Lifetime Achievement Award
Michel Bourin – Nantes University, France
Michel Bourin is a pharmacology professor affiliated with Nantes University, France, whose scholarly work focuses on psychopharmacology, mood disorders, anxiety disorders and bipolar disease. His research publications address experimental models of emotional disorders, antidepressant activity, neurochemical mechanisms and pharmacological treatment. His academic profile provides a basis for considering his contributions to pharmaceutical and psychiatric research in the context of lifetime achievement recognition.[1]
1. Abstract
This article presents the academic profile and research contributions of Michel Bourin in pharmacology and psychopharmacology. His published work includes investigations into anxiety and depression models, antidepressant mechanisms, bipolar disorder and pharmacological treatments. His publication record and citation indicators provide measurable evidence of sustained scholarly activity. The profile is considered for the Lifetime Achievement Award of the International Top Pharmaceutical Awards, based on the available academic information and publication record.[1]
2. Keywords
Michel Bourin; Lifetime Achievement Award; pharmacology; psychopharmacology; bipolar disorders; anxiety disorders; depression research; antidepressants; pharmaceutical sciences; experimental pharmacology.
3. Introduction
Psychopharmacology examines how pharmaceutical substances influence neurological processes and psychiatric conditions. Research in this field supports the investigation of therapeutic mechanisms, experimental models and treatment strategies. Michel Bourin’s publications address several of these themes, particularly anxiety, depression and mood disorders, connecting experimental pharmacology with clinically relevant research questions.[2]
4. Research Profile
The available Google Scholar profile identifies Michel Bourin as a professor of pharmacology at Université de Nantes and lists mood disorders, anxiety disorders and bipolar disease among his research interests. The supplied Scopus information reports 441 documents, 13,383 citations and an h-index of 58. The uploaded Google Scholar snapshot, dated 10 November 2026, separately reports 20,417 citations and an h-index of 69; these indicators come from different databases and should not be directly equated.[1]
5. Research Contributions
His research includes experimental approaches to anxiety and antidepressant activity, including the mouse light/dark box and forced swimming tests. These models have been discussed in studies examining behavioural responses and the evaluation of potential pharmacological compounds. His collaborative publications also address dopamine dysregulation and biological markers associated with psychiatric disorders, contributing to interdisciplinary discussion in neuropsychopharmacology.[2] [3]
6. Publications
Michel Bourin’s research has made contributions to pharmacology, psychopharmacology and the understanding of psychiatric disorders, particularly anxiety, depression and bipolar disease. His academic work explores behavioural models, antidepressant mechanisms, neurochemical pathways and pharmacological treatment approaches. Through sustained research and scientific collaborations, he has contributed to advancing knowledge of experimental pharmacology and psychiatric drug evaluation. His publication record reflects long-standing engagement with interdisciplinary pharmaceutical and biomedical research, supporting his consideration for lifetime achievement recognition.[2]
7. Research Impact
The citation records associated with Bourin’s publications indicate continuing scholarly engagement with research on anxiety, depression and pharmacological evaluation. His collaborative work provides literature relevant to experimental methodology and psychiatric drug research. These contributions form part of the broader scientific discussion surrounding psychopharmacological investigation and therapeutic development.[2] [4]
8. Award Suitability
His documented publication history, interdisciplinary collaborations and research contributions in pharmacology provide relevant grounds for consideration for the Lifetime Achievement Award. His work reflects sustained engagement with important questions in psychiatric pharmacology and pharmaceutical research. Final recognition remains subject to the award committee’s independent evaluation and verification of supporting academic records.[3]
9. Conclusion
Michel Bourin’s academic record represents an established contribution to pharmacology and psychopharmacological research. His publications on anxiety, depression, bipolar disorders and experimental drug evaluation demonstrate the breadth of his scholarly interests. His profile merits consideration for recognition through the International Top Pharmaceutical Awards.
10. External Links
11. References
- Bourin, M., & Hascoët, M. (2003). The mouse light/dark box test. European Journal of Pharmacology, 463, 55–65. https://doi.org/10.1016/S0014-2999(03)01274-3.
- Petit-Demouliere, B., Chenu, F., & Bourin, M. (2005). Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology, 177, 245–255. https://doi.org/10.1007/s00213-004-2048-7.
- Bandelow, B., et al. (2017). Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II. The World Journal of Biological Psychiatry, 18, 162–214. https://doi.org/10.1080/15622975.2016.1190867.
- Nutt, D., et al. (2007). The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. Journal of Psychopharmacology, 21, 461–471. https://doi.org/10.1177/0269881106069938.
- Elsevier. (n.d.). Scopus author details: Michel Bourin, Author ID 24282557300. Scopus. Scopus Author Profile.